Neutralizing polyclonal antibody to respiratory syncytial virus (RSV) has been shown to be an effective prophylactic agent when administered intravenously in high-risk infants. This study describes the generation of a humanized monoclonal antibody, MEDI-493, that recognizes a conserved neutralizing epitope on the F glycoprotein of RSV. The affinity of MEDI-493 was found to be equal to or slightly better than an isotype-matched chimeric derivative of the parent antibody. In plaque reduction, microneutralization, and fusion-inhibition assays, MEDI-493 was significantly more potent than the polyclonal preparation. Broad neutralization of a panel of 57 clinical isolates of the RSV A and B subtypes was demonstrated. Pretreatment of cotton rats with MEDI-493 resulted in 99% reduction of lung RSV titers at a dose of 2.5 mg/kg, corresponding to a serum concentration of 25 -30 mg/mL. Further, MEDI-493 did not induce increased RSV infection or pathology in either a primary or a secondary challenge.
Respiratory syncytial virus (RSV) is the leading cause of ease. It has recently become evident that some adults, especially the elderly, have symptomatic RSV infections more frequently serious lower respiratory tract disease in infants and children [1 -3] . The yearly epidemic nature of RSV infection is evident than had been previously reported [12] . Several epidemics also have been reported among nursing home patients and institu-worldwide, but the incidence and severity of RSV disease in a given season vary by region [4] . In temperate regions of the tionalized young adults [13, 14] . Finally, RSV may cause serious disease in immunosuppressed persons, particularly bone northern hemisphere, it usually begins in late fall and ends in late spring. Primary RSV infection occurs most often in chil-marrow transplant patients [15] . Treatment options for established RSV disease are limited. dren from 6 weeks to 2 years of age and uncommonly in the first 4 weeks of life during nosocomial epidemics [5] . Children Severe RSV disease of the lower respiratory tract often requires considerable supportive care, including administration of hu-at increased risk from RSV infection include preterm infants [5] and children with bronchopulmonary dysplasia [6] , congenital midified oxygen and respiratory assistance [16] . The only drug approved for treatment of infection is the antiviral agent ribavi-heart disease [7] , congenital or acquired immunodeficiency [8, rin [17] . It has been shown to be effective in the treatment of 9], and cystic fibrosis [10] . The fatality rate in infants with RSV pneumonia and bronchiolitis, modifying the course of heart or lung disease who are hospitalized with RSV infection severe RSV disease in immunocompetent children [18] . Howis 3% -4% [11] . ever, ribavirin has had limited use because it requires prolonged RSV infects adults as well as infants and children. In healthy aerosol administration and because of concerns about its potenadults, RSV causes predominantly upper respiratory tract distial risk to pregnant women who may be exposed to the drug during its administration in hospital settings. While a vaccine might prevent RSV infection, no vaccine is yet licensed for this indication. A major obstacle to vaccine JID 1997; 176 (November) immaturity of the neonatal immune response together with high and B subtypes have been described for both the G and F proteins, the more significant antigenic differences reside on titers of maternally acquired RSV antibody may be expected to reduce vaccine immunogenicity in the neonatal period [ 27] . Hemming et al. [28] recognized the possible utility of RSV antibody in treatment or prevention of RSV infection A, B, and C). Neutralization studies were performed against a panel of RSV strains isolated from 1956 to 1985 that demon-during studies involving the pharmacokinetics of an intravenous immune globulin (IVIG) in newborns suspected of having strated that epitopes within antigenic sites A and C are highly conserved, while the epitopes of antigenic site B are variable. neonatal sepsis. They noted that 1 infant, whose respiratory secretions yielded RSV, recovered rapidly after IVIG infusion.
In the current study, we describe the construction, expression, and biologic properties of MEDI-493, a humanized version of Subsequent analysis of the IVIG lot revealed an unusually high titer of RSV neutralizing antibody. This same group of one of the antibodies directed to the A site, MAb 1129. investigators then examined the ability of hyperimmune serum or immune globulin, enriched for RSV neutralizing antibody, Materials and Methods to protect cotton rats and primates against RSV infection [29 -33] . Results of these studies suggested that RSV neutralizing Virus and antibodies. RSV Long and 18537 strains were used as A and B subtype laboratory viruses in these studies. In addition, antibody given prophylactically inhibited respiratory tract repliclinical isolates were obtained from centers in Denver, Houston, cation of RSV in cotton rats. When given therapeutically, RSV Long Beach (CA), Nashville, Rochester (NY), St. Louis, and antibody reduced pulmonary viral replication both in cotton Washington, DC. The viruses were passaged and titered using rats and in a nonhuman primate model. Furthermore, passive HEp-2 cells. MAb 1129 was described by Beeler and Coelingh infusion of immune serum or immune globulin did not produce [38] . A MEDI-493-resistant variant of RSV Long was selected enhanced pulmonary pathology in cotton rats subsequently as described [38] . The pan F protein, C-site-specific MAb 133challenged with RSV. Recent clinical studies have conclusively 1H, was used in the F protein-specific ELISA to detect viral demonstrated the ability of this passively administered RSV replication. This MAb has been described by Anderson et al. [39] hyperimmune globulin (RSV IVIG) to protect at-risk children and was obtained from Chemicon (Temecula, CA). RSV IVIG, from severe lower respiratory infection by RSV [34, 35] . While lots 4 and 12, were obtained from Massachusetts Public Health Biologics Laboratory (Boston). These lots had microneutralization this is a major advance in preventing RSV infection, this treattiters (5% solution) of 1/7000 and 1/5543, respectively. ment poses certain limitations in its widespread use. First, RSV Construction and expression of MEDI-493. MEDI-493 VH IVIG must be infused intravenously over several hours to and VL genes were assembled de novo using both polymerase achieve an effective dose. Second, the concentrations of active chain reaction and site-directed mutagenesis as described by Kunmaterial in hyperimmune globulins are insufficient to treat kel [40] . The VL and VH segments were combined with cDNA adults at risk. segments corresponding to C-kappa and C-gamma-1 (nG1m) and
One way to improve the specific activity of the immunoglobinitially expressed transiently in COS-1 cells using a CMV immeulin would be to develop one or more highly potent RSV diate-early promoter. Stable cell lines expressing MEDI-493 from neutralizing monoclonal antibodies (MAbs). Such MAbs mouse myeloma cells, NS0, were generated as described by Bebshould be human or humanized in order to retain favorable bington et al. [41] . pharmacokinetics and to avoid generating a human anti-mouse Binding analysis. Immunoaffinity-purified F protein from RSV A2 was provided by P. Paradiso (Wyeth-Lederle Vaccines antibody response, as repeat dosing would be required throughand Pediatrics, Rochester, NY). To coat the chip surface with out the RSV season. Two glycoproteins, F and G, on the surface antigen, a 10 nM solution of RSV F protein was injected over an of RSV have been shown to be targets of neutralizing antibod- [16, 21] . These two proteins are also primarily responsible carbodiimide-activated CM5 sensor chip (Biacore, Piscataway, NJ) for viral recognition and entry into target cells; G protein binds [42] . Following this, unreacted active ester groups were reacted to a specific cellular receptor and the F protein promotes fusion the RSV F protein surface using looped sequential injections at a flow rate of 10 mL/min for 4 min. A 4-min dissociation period tion. Although antigenic and structural differences between A was followed by a regeneration step consisting of 10 mL of 100 vol) Hanks' balanced salt solution. The resulting suspension was quantified for virus content by plaque assay using HEp-2 cells. mM HCl. Individual rate constants for the association and dissociation were calculated using Bia-evaluation software (provided by Serum MEDI-493 levels at the time of challenge were determined using an anti-human IgG ELISA. Biacore).
Plaque-reduction assay. Serial dilutions of antibody were pre-For pathology, the lung tissues were trimmed, dehydrated through graded alcohols, perfused with xylene, processed through pared in 96-well microtiter dishes using Hanks' balanced salt solution as diluent. An equal volume of RSV suspension previously paraffin, sectioned at 5 mm, stained with hematoxylin-eosin, and interpreted microscopically in a blinded manner. Control slides titered to give 50 pfu was added to each well to achieve a 50-mL final reaction mixture. After a 1-h incubation at 23ЊC, 50 mL of representing uninfected and RSV-infected cotton rat tissues were examined. In addition, control slides from cotton rats vaccinated this mixture was then added to each of three wells of a 24-well plate (Costar, Cambridge, MA) containing confluent HEp-2 cells, with a formalin-inactivated vaccine and infected with RSV were also examined. Lesions associated with RSV infection in the cotton from which all but 15 mL of medium had been aspirated. After 1 h at 37ЊC, 1 mL of warm plaquing medium (MEM containing 1% rats were characterized by the presence of bronchiolitis and, in some animals, focal interstitial pneumonia. The bronchiolitis in-methyl cellulose, 2% fetal calf serum, 0.002 M L-glutamine, and 50 mg/mL gentamycin) was added, and plates were incubated for volved single or multiple airways and was characterized by both epithelial changes and the presence of inflammatory cell infiltrates 5-6 days at 37ЊC until plaque formation was evident. The overlay was removed by inversion, and the cell layer was fixed and stained scattered around the bronchioles. Normal bronchiolar epithelium had relatively small, basally located nuclei in cells with abundant with 0.1% crystal violet in 5% glutaraldehyde for 30-60 min, dried at room temperature, and then counted. The concentration apical cytoplasm. In contrast, bronchiolar epithelial cells in inflamed areas were hypertrophic and characterized by the presence of antibody resulting in 50% reduction in plaques relative to the virus control without antibody (EC 50 ) was estimated from an inter-of karyomegalic nuclei located centrally in the cell. Indistinct syncytial bronchiolar epithelial cells were observed in an occasional polated plot of the data.
Microneutralization assay. The microneutralization assay is a affected area. An apoptotic nucleus was rarely observed; infrequent mitoses were also seen. Inflammatory infiltrates consisted predomi-modification of the procedures described by Anderson et al. [43] . Antibody dilutions were made in triplicate in a 96-well plate.
nantly of mononuclear cells (mostly macrophages with few lymphocytes) and fewer neutrophils around the affected airways and Seventy-five TCID 50 of RSV were then added to each well and incubated for 2 h at 37ЊC. HEp-2 cells (2.5 1 10 4 ) were then infiltrating the smooth muscle to the mucosa. In the lung, alveolar septa were thickened by proliferation of alveolar epithelial cells added to each well and cultured for 5 days at 37ЊC in 5% CO 2 . After 5 days, the medium was aspirated, and cells were washed and very slight infiltrates of macrophages. The extent of pathology was graded: 0 (normal), 1 (minimal), 2 (mild), 3 (moderate), or 4 and fixed with acetone. Viral replication was then measured using an F protein-specific ELISA. The amount of viral antigen present (marked). in wells at the different antibody dilutions was plotted for each sample, and the data were analyzed using a four-parameter curve body concentration for each sample that reduced viral replication [44] . To design the variable region sequences, the three-dimento 50% of that in virus-infected control wells was then calculated sional structure of the MAb 1129 Fv region was modeled by and expressed as the EC 50 . For evaluating the neutralization of simple substitution of the residues from the MAb 1129 VL and clinical isolates by MEDI-493, the antibody concentration was VH sequence into the coordinates of corresponding residues in fixed at 400 mg/mL and the virus dilution was varied.
the known crystal structure of the MCPC603 antibody [45] . to RSV F protein was assessed by ELISA in comparison to a antibody was mixed with virus (RSV Long) prior to infection, while in the fusion-inhibition assay, MEDI-493 was added 4 similarly expressed chimeric version of 1129. The results of this assay indicated that the affinity of MEDI-493 was equiva-h after cells were infected with RSV. The EC 50 for MEDI-493 was calculated to be 0.10 { 0.03 mg/mL in the microneutraliza-lent to or slightly better than chimeric 1129 (data not shown). The K d of both antibodies was estimated to be 1 -2 nM (based tion assay and 0.17 { 0.6 mg/mL in the fusion-inhibition assay (average of three assays each { SD). These values compared on the EC 50 of each in the ELISA). Subsequently, a stable MEDI-493 expression cell line was constructed in mouse my-favorably with EC 50 values for RSV IVIG (lot 12) of 2.58 { 0.37 mg/mL and 5.25 { 0.23 mg/mL, respectively, demonstra-eloma cell line NS0 using glutamine synthetase selection and amplification using methionine sulfoximine [41] . Additional ting a 20-to 30-fold enhanced potency of MEDI-493 compared with the polyclonal product. studies described below were performed using MEDI-493 purified from this cell line, which produces antibody at Ç1 g/L of These data indicated potent neutralization of laboratory strains of RSV by MEDI-493. In order to survey the spectrum culture.
To obtain a better understanding of the binding properties of MEDI-493 neutralization of contemporary clinical isolates of RSV, a total of 57 isolates consisting of 34 A and 23 B of MEDI-493 to RSV F protein, including kinetic parameters, a real-time biosensor system (Biacore) was used. RSV F protein subtype isolates were analyzed. In this assay, a fixed concentration of MEDI-493 was added to serial dilutions of the untitered was used to coat the sensor chip (RU [resonance units]-max Å 250), and binding and dissociation of MEDI-493 were mea-viruses. Each of these isolates was neutralized by MEDI-493. Representative assays of A and B subtypes are shown in figure sured at various concentrations (figure 2). Using these kinetic data, the k(on) was calculated to be 3.0 1 10 5 M 01 s 01 , and 4. As a control for this assay, a resistant virus preparation, generated by plaquing and passaging in the presence of MEDI-the k(off) was 4.3 1 10 04 s 01 giving a K d of 1.4 nM, similar to that observed in the ELISA assay with the COS-1 -derived 493, was tested in the same assay and found to be susceptible to neutralization by RSV IVIG but not by MEDI-493. antibody.
Three different in vitro neutralization assays were used to The cotton rat model of RSV infection was used to demonstrate potency of MEDI-493 in vivo. In each experiment, assess the ability of MEDI-493 to neutralize RSV. First, we used a plaque-reduction assay to evaluate the neutralization MEDI-493 was administered 1 day before intranasal challenge with 10 5 pfu of RSV. Figure 5 shows the protection of animals of either A (Long) or B (18537) strains of RSV. MEDI-493 effectively neutralized both types of RSV in a dose-dependent given antibody intramuscularly and challenged with either RSV Long or RSV 18537. MEDI-493 is potent against both sub-manner ( figure 3) . The EC 50 s for MEDI-493 neutralization of RSV Long and 18537 were similar, Ç2 mg/mL in this assay.
types, reducing viral replication by ú99% at a dose of 2.5 mg/ kg in each case. As shown in table 1, ú99% reduction in In addition, MEDI-493 was evaluated in microneutralization and fusion-inhibition assays. In the microneutralization assay, pulmonary RSV was achieved also at an intravenous dose of 2.5 / 9d39$$no40 09-23-97 11:35:29 jinfa UC: J Infect / 9d39$$no40 09-23-97 11:35:29 jinfa UC: J Infect mg/kg. In this experiment, the serum antibody concentration at the time of RSV challenge was Ç30 mg/mL at the 2.5 mg/kg dose. Two series of additional cotton rat studies were done to assess potential enhancement of virus infectivity or RSV-induced histopathology after primary or secondary RSV challenge. In the first, a dose-ranging study was performed in the cotton rat model to determine whether the presence of MEDI-493 at noninhibitory levels could enhance viral replication or virus-induced pathology during a primary infection or enable the selection of antibody-resistant variants in vivo. Groups of 4 animals each were given bovine serum albumin or various concentrations of MEDI-493 intramuscularly. At 24 h later, all animals were challenged with 10 5 pfu of RSV Long. Four days later, the animals were sacrificed, and the lung tissue was analyzed for RSV levels and fixed and prepared for histopathology. The results of this study indicated that no enhancement of viral replication or RSV-specific histopathology was observed on primary challenge in the presence of MEDI-493. In order to test for the presence of antibody-resistant mutants, the lung homogenates were incubated with 0.1 mg/mL MEDI-493 at 4ЊC for 1 h before addition to HEp-2 cells. Only 1 plaque was observed in the entire experiment, from an animal receiving a 0.0032-mg/kg dose.
A second set of experiments was designed to determine if increased pathologic changes would occur after reinfection in animals that received MEDI-493 prior to primary infection. Cotton rats were divided into 3 groups. Group 1 animals (n Å 12) received 10 mg/kg bovine serum albumin and group 2 (n Å 12) received 10 mg/kg MEDI-493 intravenously 1 day prior to challenge with RSV (10 5 pfu/Long strain). Group 3 (n Å 8) was not dosed and was mock-challenged with medium only. Four animals each from groups 1 and 2 were sacrificed 4 days after infection, and pulmonary virus titers were determined. Biweekly blood samples were taken from the remaining animals, and MEDI-493 levels were determined by ELISA. After 8 weeks, when MEDI-493 was no longer detectable, the remaining animals were rechallenged with a low dose of RSV (10 3 pfu) and sacrificed on day 4 after challenge. The lower dose was used so that any increased viral replication would be observable. Lungs were divided and prepared for histopathology, and virus was titrated as described above. The results of the challenge and rechallenge are summarized in table 2. Again, no enhancement of viral replication or virus-induced pathology was observed. In fact, animals previously protected from lower respiratory tract infection by MEDI-493 were completely resistant to a subsequent challenge after clearance of antibody, indicating the presence of MEDI-493 does not impede development of a protective immune response to RSV. and the severity of RSV-related lower respiratory tract infection ministration, we have developed a humanized MAb, MEDI-493. in at-risk infants [34, 35] . This development was a major step forward in the care of premature infants and others at significant It is expected that a humanized RSV-specific MAb would need to have several important properties. It would be important risk for RSV morbidity. However, broad use of this product may be hampered by the time required for intravenous adminis-to retain the affinity of the parent MAb, have potent neutralizing and fusion-inhibition capacity, and react with the majority of tration of the polyclonal preparation and the large volume of RSV IVIG required to achieve adequate titers to treat adults recent clinical isolates of both A and B subtypes of RSV. In addition, antiviral activity should be demonstrated in a relevant at risk for RSV. In order to achieve a higher specific activity of RSV-specific antibodies to facilitate alternate routes of ad-animal model of RSV infection, and the antibody should not tralizing antibodies, possibly by cross-linking of Fc receptor molecules on the surface of the target cell [51] . Although this phenomenon has been demonstrated for RSV infection in vitro, induce increased viral infection or lung pathology upon primary or secondary RSV infection. The studies performed demonstrate its significance to the in vivo infection process remains to be demonstrated [52] . A second, more serious phenomenon, is that MEDI-493 satisfies all of these criteria.
In addition to MEDI-493, several other MAbs have been that of enhanced pathology, which occurred when persons previously immunized with a formalin-inactivated RSV vaccine described that may have potential in RSV prophylaxis or treatment (or both). Tempest et al. [46] developed a humanized (FI RSV) were exposed to RSV during a natural infection [19, 20] . This histopathology has been duplicated and examined in MAb to a linear epitope on RSV, while Crowe et al. [47] isolated an RSV-specific human Fab fragment from an Esche-animal models, including mice and cotton rats [53, 54] . These studies are consistent with a mechanism of pathology that is richia coli phage display library. Both of these compounds were shown to neutralize RSV. It appears from the available T cell-dependent. Immunization with FI RSV appears to lead to the generation of primarily nonneutralizing antibodies and data that these antibodies recognize epitopes on the F protein distinct from each other and from MEDI-493 (1129), which priming of the Th2 subset of CD4 helper T cells [54, 55] . Thus, antibody may play a minor role in this setting. recognizes a conformational epitope. Although we do not believe that more than one MAb is required for prophylaxis, it
In this study, antibody-dependent enhancement of viral replication was not observed during a primary infection with sub-may be desirable to use a cocktail of MAbs in a therapeutic mode, where the virus burden is likely to be substantially prophylactic doses of MEDI-493 in the cotton rat. Furthermore, no enhancement of histopathology was observed in either a higher, so as to limit the potential for escape mutant generation.
Each of the assays used to evaluate MEDI-493 has been primary infection or upon rechallenge of previously infected animals. In addition, MEDI-493 did not impede the develop-advocated as a surrogate for prophylaxis of RSV disease. However, some of these assays may be more valuable than others in ment of protective immune responses, as shown in the rechallenge study. This result differs from results from a recent study predicting in vivo efficacy. Polyclonal IVIG potent in plaquereduction assays has been shown to induce protection in cotton using RSV IVIG in a mouse model of infection [56] but is consistent with results from previous studies conducted in the rats and at-risk infants; however, some human MAbs, which are effective in this in vitro assay, failed to induce protection cotton rat model [29] . In summary, MEDI-493 appears to be a potent, broadly in cotton rats (Bansal G, Johnson S, unpublished data). On the other hand, the microneutralization assay has been used to reactive neutralizing humanized antibody to a conserved epitope of the F protein of RSV and is substantially more potent screen donors for manufacture of RSV IVIG [48] and yields fewer false positives. In addition, Taylor et al. [49] observed than a polyclonal hyperimmune IVIG preparation that protected high-risk infants against RSV infection. Thus, MEDI-493 ap-that a fusion-inhibition assay was most predictive of the ability of certain MAbs to protect mice from RSV. MEDI-493 is pears to be a promising candidate for the prevention of RSV. On the basis of the potency and safety of MEDI-493 demon-potent in a dose-dependent manner in all three assays and in the cotton rat model. strated in these studies, clinical trials have been initiated to evaluate the safety and efficacy of this molecule as a prophylac-The cotton rat model of RSV infection has proven extremely useful in understanding the biology of RSV infection and in tic agent for RSV-related lower respiratory tract infection in infants. evaluating potential prophylactic or therapeutic agents in terms of potency and certain safety issues. The correlation of a spe-
